



LIPOSOME-LIKE FUCOPEPTIDES AS SIALYL LEWIS X MIMETICS

Chun-Cheng Lin,¹ Teiji Kimura,¹ Shih-Hsiung Wu,^{1,†} Gabriele Weitz-Schmidt,² and
Chi-Huey Wong^{1,*}

*Department of Chemistry, The Scripps Research Institute,
10550 North Torrey Pines Road, La Jolla, CA 92037, U.S.A.*


Abstract: Several fucodipeptides and their liposome-like derivatives were prepared and tested as inhibitors of sialyl Lewis X binding to E-selectin. It has been found that *trans*-hydroxyproline (D or L) can be used to mimic the galactose residue of sialyl Lewis X, and the mimetic containing 3,4-dihydroxy-D-proline is the most active with IC₅₀ value (50 μ M) 10-fold greater than sialyl Lewis X. Derivatization of a hydroxythreonine-containing fucodipeptides into a covalent liposome-like derivative, however, provides a mimetic with only IC₅₀ ~ 30 μ M.

Copyright © 1996 Elsevier Science Ltd

The early stage of neutrophil migration from the blood stream to the site of inflammation or tissue injury occurs with the rolling adhesion of neutrophils to vascular endothelium.¹ The adhesion process involves the interaction of sialyl Lewis X (SLe^x, Figure 1), a terminal tetrasaccharide of cell-surface glycoproteins and glycolipids, and the endothelial leukocyte adhesion molecule-1 (E-selectin).² Inhibition of the SLe^x/E-selectin interaction has been shown to be effective in animal models of certain inflammatory diseases such as reperfusion injury.³ Although the synthesis of SLe^x on a large scale has been developed for clinical evaluation,⁴ this natural saccharide is relatively weak regarding its activity (IC₅₀ ~ 0.5 mM) against E-selectin and can only be used in its injectable form for acute symptoms as it is orally inactive and unstable in the blood stream.⁵ Development of SLe^x mimetics with higher affinity for the receptor and better activity and stability against glycosidase⁵ has been of current interest.⁶

The bound conformation of SLe^x to E-selectin⁷ and the functional groups essential for recognition by E-selectin have been determined to include the carboxylate group of the NeuAc moiety, the 2-, 3-, and 4-OH groups of the fucose moiety and the 4- and 6-OH groups of the galactose moiety.⁸ This recognition model provides useful information for the design of mimetics,⁶ and our effort in this regard has shown that α -O-L-fucosyl-L-threonine ethyl ester coupled with γ -hydroxy-L-Thr (1), α -hydroxymethyl-L-Ser (2) or hydroxyproline (3 and 4) gives mimetics with activity^{6c} equivalent or greater than SLe^x (Figure 1). We report here further investigation of other hydroxyproline and liposome-like derivatives as inhibitors of E-selectin.

We chose α -O-fucosyl-L-threonine ethyl ester as a core structure^{6c} linked to D-hydroxythreonine or hydroxyproline to mimic the active conformation of the Le^x portion of SLe^x. Since the *trans*-hydroxyamine moiety of Thr is equivalent to the *trans*-diol orientation of the GlcNAc moiety in SLe^x, the O-fucosyl-Thr derivative is expected to mimic the Fuc- α -1,3-GlcNAc portion of SLe^x. Incorporation of a designed amino acid to the amine group via a peptide linkage will not only provide the functionality's equivalent to the Gal moiety of SLe^x but also rigidify the conformation. A glutaryl group was used to provide the negative charge equivalent to the NeuAc moiety. In addition, (1*R*, 2*R*)-2-aminocyclohexanol was used to replace the Thr moiety as this cyclic aminoalcohol was also shown to be an effective template.^{6d}


Figure 1. Sialyl Lewis X and designed mimetics with IC_{50} against E-selectin

The IC_{50} values of **1-9** are shown in Figure 1 ($SLe^x = 0.5$ mM). Interestingly, compound **4** is 10-fold better while compound **9** is 10-fold weaker than SLe^x in binding to E-selectin.⁹ Compounds **3** and **6** are slightly better, and as expected, **5** and **7** are weaker than SLe^x (due to the inappropriate orientation of the *cis*-OH group from the hydroxyproline residue). Surprisingly, the β -isomer **8** is essentially as active as the α -isomer. L-Threonine is apparently better than the 2-amino-cyclohexanol as a template for the design of SLe^x mimetics in this study, though the aminocyclohexanol template works very well when γ -hydroxy-L-threonine is used to mimic the Gal residue.^{6c} The liposome-like mimetics **13** and **14** ($IC_{50} = 0.5$ mM), Scheme 1, do not show good activities as expected,¹⁰ probably because the dihexadecyl L-glutamate tail can not form a stable liposome with phosphatidylcholine. The covalent liposome-like¹¹ mimetics **22** and **24** were then prepared (Scheme 2), and interestingly **22** is relatively active ($IC_{50} = 30$ μ M) but **24** is inactive. Whether the positive charge of **24**


contributes to the negative result remains to be investigated. It is noted that **22** and **24** were tested directly as inhibitors of E-selectin and work is in progress to formulate compounds **2-8** as liposomes for inhibition analysis.

With regard to the synthesis, compounds **5-9** were prepared according to the procedures described previously.^{6c,12} Schemes 1 and 2 illustrate the synthesis of lipids **13**, **14**, **22**, and **24**. Azide aldehyde, which was derived from Swern oxidation of azido alcohol **14**,¹³ was linked to dihexadecyl L-glutamate¹⁴ via reductive amination (65%) followed by catalytic hydrogenation (100%), to give the anchor moiety **11**. Compound **11** was coupled with mimetic moiety **12**¹⁵ (52%) and hydrogenated to give the desired lipid **13** (60%). Compound **14** was synthesized similarly.¹⁶ Liposomes of **13** and **14** were prepared¹⁷ with phosphatidylcholine **15** containing 5% of **13** or **14** in 20 mM HEPES buffer (pH 7.2), using the probe sonication method. To synthesize polymerized liposome, compound **16**¹⁵ was coupled with **17**¹⁵ followed by hydrogenation to yield **18**. The lipid conjugate **20** was synthesized by treating active ester **19** with **18** in DMF and Et₃N.¹⁸ The liposome of **20** (5 mol%) with **21** or **23** were formed as described in the scheme. The liposomes were then polymerized by irradiating 254 nm UV lamp at 0 °C to generate lipid polymers **22** and **24**.¹⁹

Scheme 1^a



^aConditions: (a) Swern oxidation; (b) 1',3'-dihexadecyl L-glutamate·TsOH salt, NaCNBH₃/THF-MeOH; (c) H₂, Pd/C, 1 N HCl/MeOH; (d) **12**, EDC, HOBT, CH₂Cl₂, 6 h; (e) H₂ (1 atm), Degussa type Pd(O)EtOH/H₂O (2:1), 5 h.

Scheme 2^a

^aConditions: (a) **17**, EDC, HOBT, CH₂Cl₂, 6 h, 79%; (b) H₂, Pd(OH)₂/C, EtOH/H₂O/dioxane/AcOH (2:1:2:1), 94%; (c) **19**, DMF, Et₃N, 1 day, 84%; (d) (i) **21**, sonication/HEPES buffer, heat; (ii) *hν*, 0 °C.

References and Notes

[†]On sabbatical leave from Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.

- (a) Levy, D. E.; Tang, P. C.; Musser, J. H. *Annu. Rep. Med. Chem.* **1994**, 215. (b) Lasky, L. A. *Science* **1992**, 258, 6224.
- (a) Phillips, M. L.; Nudelman, E.; Gaeta, F. C. A.; Perez, M.; Singhal, A. K.; Hakomori, S.; Paulson, J. C. *Science* **1990**, 250, 1132. (b) Walz, G.; Aruffo, A.; Kolanus, W.; Bevilacqua, M.; Seed, B. *Science* **1990**, 250, 1130. (c) Lowe, J. B.; Stoolman, L. M.; Nair, R. P.; Larsen, R. D.; Berhend, T. L.; Mark, R. M. *Cell* **1990**, 63, 474. For reviews on the selectin-carbohydrate interactions, see: (d) Lasky, L. A. *Annu. Rev. Biochem.* **1995**, 64, 113. (e) Springer, T. A. *Cell* **1994**, 76, 301.
- (a) Buerke, M.; Weyrich, A. S.; Zheng, Z.; Gaeta, F. C. A.; Forrest, M. J.; Lefer, A. M. *J. Clin. Invest.* **1994**, 1140. (b) Mulligan, M. S.; Paulson, J. C.; Frees, S. D.; Zheng, Z. L.; Lowe, J. B.; Ward, P. A. *Nature* **1993**, 364, 149. (c) Murohara, T.; Margiotta, J.; Phillips, L. M.; Paulson, J. C.; DeFrees, S.; Zalipsky, S.; Guo, L. S. S.; Lefer, A. M. *Cardiorascular Res.* **1995**, 30, 965.
- Ichikawa, Y.; Lin, Y.-C.; Dumas, D. P.; Shen, G.-J.; Garcia-Junceda, E.; Williams, M. A.; Bayer, R.; Ketcham, C.; Walker, L. E.; Paulson, J. C.; Wong, C.-H. *J. Am. Chem. Soc.* **1992**, 114, 9283.
- SLe^x is sensitive to α -fucosidase and neuraminidase.
- (a) Dupré, B.; Bui, H.; Scott, I. L.; Market, R. V.; Keller, K. M.; Beck, P. J.; Kogan, T. P. *Bioorg. Med. Chem. Lett.* **1996**, 6, 569. (b) Ramphal, J. Y.; Hiroshige, M.; Lou, B.; Gaudino, J. J.; Hayashi, M.; Chen, S. M.; Chiang, L. C.; Gaeta, F. C. A.; DeFrees, S. A. *J. Med. Chem.* **1996**, 39, 1359. (c) Lin, C.-C.; Shimazaki, M.; Heck, M.-P.; Aoki, S.; Wang, R.; Kimura, T.; Ritzen, H.; Takayama, S.; Wu, S.-H.; Weitz-Schmidt, G.; Wong, C.-H. *J. Am. Chem. Soc.* **1996**, 118, 6826 (also ref 18 cited there). (d) Wang, R.; Wong, C.-H. *Tetrahedron Lett.* **1996**, 31, 5427.
- Scheffler, K.; Ernst, B.; Katopodis, A.; Magnani, J. L.; Wang, W. T.; Weisemann, R.; Peters, T. *Angew. Chem. Int. Ed. Engl.* **1995**, 34, 1841. (b) Cooke, R. M.; Hale, R. S.; Lister, S. G.; Shah, G.; Weir, M. P. *Biochemistry*, **1994**, 33, 10591. (c) Hensley, P.; McDevitt, P. J.; Brooks, I.; Trill, J. J.; Feild, J. A.; McNulty, D. E.; Connor, J. R.; Griswold, D. E.; Vasant Kumar, N.; Kopple, K. D.; Carr, S. A.; Dalton, B. J.; Johanson, K. J. *J. Biol. Chem.* **1994**, 269, 23949.
- (a) Stahl, W.; Sprengard, U.; Kretzschmar, G.; Kunz, H. *Angew. Chem. Int. Ed. Engl.* **1994**, 33, 2096. (b) Ramphal, J. Y.; Zheng, Z.-L.; Perez, C.; Walker, L. E.; DeFrees, S. A.; Gaeta, F. C. A. *J. Med. Chem.* **1994**, 37, 3459. (c) DeFrees, S. A.; Kosch, W.; Way, W.; Paulson, J. C.; Sabesan, S.; Halcomb, R. L.; Huang, D.-H.; Ichikawa, Y.; Wong, C.-H. *J. Am. Chem. Soc.* **1995**, 117, 60. (d) Brandley, B. K.; Kiso, M.; Abbas, S.; Nikrad, P.; Srivastava, O.; Foxall, C.; Oda, Y.; Hasegawa, A. *Glycobiology* **1993**, 3, 633. (e) Tyrrell, D.; James, P.; Rao, N.; Foxall, C.; Abbas, S.; Dasgupta, F.; Nashed, M.; Hasegawa, A.; Kiso, M.; Asa, D.; Kidd, J.; Brandley, B. K. *Proc. Natl. Acad. Sci. U.S.A.* **1991**, 88, 10372. (f) Nelson, R. M.; Dolish, S.; Aruffo, A.; Cecconi, O.; Bevilacqua, M. P. *J. Clin. Invest.* **1993**, 91, 1157. (g) Graves, B. J.; Crowther, R. L.; Chandran, C.; Rumberger, J. M.; Li, S.; Huang, K.-S.; Presky, D. H.; Familletti, P. C.; Wolitzky, B. A.; Burns, D. K. *Nature*, **1994**, 367, 532. (h) Kogan, T. P.; Revelle, B. M.; Tapp, S.; Scott, D.; Beck, P. J. *J. Biol. Chem.* **1995**, 270, 14047.
- Weitz-Schmidt, G.; Stokmaier, D.; Scheel, G.; Nifant'ev, N. E.; Tuzikov, A. B.; Bovin, N. V. *Anal. Biochem.* **1996**, 238, 184. All compounds were tested three times and an average value was taken ($\pm 10\%$ error). All compounds show a dose-dependent response.
- SLe^x liposome was shown to be much more active than the monomer; DeFrees, S. A.; Phillips, M. L.; Guo, L.; Zalipsky, S. *J. Am. Chem. Soc.* **1996**, 118, 1601.
- The covalent liposome of Le^x derivatives were shown to be much more active than SLe^x; Spevak, W.; Foxall, C.; Charych, D. H.; Dasgupta, F.; Nagy, J. O. *J. Med. Chem.* **1996**, 39, 1018.
- Compound **5**: ¹H NMR (500 MHz, D₂O) δ 4.86 (d, J = 3.8 Hz, 1H_a), 4.84 (d, J = 3.9 Hz, 1H_b), 4.50 (d, J = 2.2 Hz, 1H_b), 4.48 (d, J = 2.1 Hz, 1H_a), 4.43-4.29 (m, 3H), 4.14-3.99 (m, 2H), 3.71 (dd, J = 11.4, 3.9 Hz, 1H_b), 3.64-3.56 (m, 4H_b, 6H_a), 3.49 (dd, J = 11.4, 2.7 Hz, 1H_b), 2.53-2.49 (m, 1H_a), 2.43-2.37 (m, 1H_b), 2.28 (t, J = 7.3 Hz, 2H_b), 2.30-2.20 (m, 3H_a), 2.10 (t, J = 7.5 Hz, 2H_b), 2.06 (t, J = 7.9 Hz, 2H_a), 1.94-1.90 (m, 1H_b), 1.71-1.64 (m, 2H_a, 2H_b), 1.14 (t, J = 7.2 Hz, 3H_b), 1.14 (t, J = 7.2 Hz, 3H_a), 1.11 (d, J = 6.3 Hz, 3H_a), 1.05 (d, J = 6.2 Hz, 3H_b), 1.05 (d, J = 6.6 Hz, 3H_b), 1.05-1.04 (3 H_a); ¹³C NMR (125 MHz, D₂O) δ 182.6, 182.2, 175.9, 175.6, 175.5, 175.3, 172.2, 172.2, 94.9, 94.7, 71.9, 71.3, 70.7, 70.0, 69.7, 69.7, 68.7, 68.0, 67.4, 67.3, 63.4, 63.0, 60.0, 59.6, 58.2, 57.6, 55.5, 55.1, 39.8, 37.4, 36.7, 36.5, 33.9, 33.6, 21.5, 15.6, 14.6, 13.8, 13.7, 13.6 (rotamers present in NMR); HRMS calcd for negative electrospray C₂₂H₃₅N₂O₁₂ (M-H): 519, found 519. Compound **6**: ¹H NMR (500 MHz, D₂O) δ 4.86 (d, J = 3.9 Hz, 1H_a), 4.84 (d, J = 3.8 Hz, 1H_b), 4.54 (d, J = 2.3 Hz, 1H_b), 4.49 (d, J = 2.2 Hz, 1H_a), 4.47 (br, 1H_b), 4.45 (br, 1H_a), 4.54-4.41 (m, 1H_b), 4.40-4.36 (m, 1H_a), 4.35 (qd, J = 6.3, 2.2 Hz, 1H_a), 4.30 (qd, J = 6.2, 2.4

- Hz, 1H_b), 4.17-4.08 (m, 1H), 4.05-3.97 (m, 1H), 3.67-3.51 (m, 5H_a, 6H_b), 3.44-3.41 (m, 1H_a), 2.39-2.34 (m, 1H_a), 2.32-2.12 (m, 2H_a, 1H_b), 2.27 (t, *J* = 7.4 Hz, 2H_b), 2.17 (t, *J* = 7.4 Hz, 2H_b), 2.15 (t, *J* = 7.4 Hz, 2H_a), 2.12-2.06 (m, 1H_a), 1.95 (ddd, *J* = 13.2, 9.1, 4.5 Hz, 1H_b), 1.69 (quintet, *J* = 7.4 Hz, 2H), 1.14 (t, *J* = 7.2 Hz, 3H_b), 1.13 (t, *J* = 7.1 Hz, 3H_a), 1.08 (d, *J* = 6.3 Hz, 3H_a), 1.05 (d, *J* = 6.8 Hz, 3H_b), 1.03 (d, *J* = 6.5 Hz, 3H); ¹³C NMR (125 MHz, D₂O) δ 175.7, 175.3, 175.2, 175.1, 172.2, 171.9, 94.7, 94.6, 71.9, 70.9, 70.6, 70.0, 69.7, 68.5, 67.9, 67.4, 67.3, 63.4, 63.3, 59.3, 59.1, 58.0, 57.6, 55.9, 55.0, 39.1, 37.9, 33.7, 33.1, 20.9, 15.6, 14.4, 14.2, 13.7, 13.6 (rotamers present in NMR); HRMS calcd for C₂₂H₃₆N₂O₁₂Na (M+Na): 543.2166, found 543.2148. Compound **7**: ¹H NMR (500 MHz, CDCl₃) δ 4.85 (d, *J* = 3.5 Hz, 1H), 4.42 (dd, *J* = 9.0, 5.0 Hz, 1H), 4.39-4.32 (m, 2H), 4.14-4.08 (m, 2H), 4.04-4.00 (m, 1H), 3.74 (dd, *J* = 11.4, 5.4 Hz, 1H), 3.65-3.54 (m, 4H), 3.44 (dd, *J* = 10.9, 3.5 Hz, 1H), 2.42 (ddd, *J* = 13.6, 9.1, 5.4 Hz, 1H), 2.27 (t, *J* = 7.5 Hz, 2H), 2.08 (t, *J* = 7.5 Hz, 2H), 1.89-1.85 (m, 1H), 1.67 (quintet, *J* = 7.5 Hz, 2H), 1.13 (dt, *J* = 7.2, 1.0 Hz, 3H), 1.10 (d, *J* = 6.4 Hz, 3H), 1.05 (d, *J* = 6.6 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 182.9, 175.5, 175.2, 172.2, 94.8, 71.9, 71.3, 69.9, 69.8, 68.0, 67.3, 63.3, 59.2, 57.6, 55.3, 37.0, 36.9, 33.9, 21.5, 15.6, 14.5, 13.7; HRMS calcd for C₂₂H₃₅N₂O₁₂Cs₂ (M-H+2Cs): 785.0299, found 785.0328. Compound **8**: ¹H NMR (500 MHz, D₂O) δ 4.48-4.41 (m, 4H), 4.18 (d, *J* = 7.9 Hz, 1H), 4.05 (q, *J* = 7.1 Hz, 2H), 3.64 (dd, *J* = 11.8, 3.9 Hz, 1H), 3.59 (q, *J* = 6.5 Hz, 1H), 3.57-3.45 (m, 2H), 3.43 (dd, *J* = 9.8, 3.4 Hz, 1H), 3.24 (dd, *J* = 9.8, 7.9 Hz, 1H), 2.35-2.15 (m, 5H), 1.96-1.90 (m, 1H), 1.72-1.66 (m, 2H), 1.16 (d, *J* = 6.4 Hz, 3H), 1.11 (t, *J* = 7.1 Hz, 3H), 1.08 (d, *J* = 6.5 Hz, 3H); ¹³C NMR (125 MHz, D₂O) δ 180.1, 175.0, 174.9, 171.8, 103.7, 76.7, 72.9, 70.1, 68.4, 63.3, 63.2, 59.0, 57.4, 55.9, 46.9, 37.6, 34.6, 33.5, 20.6, 18.5, 15.7, 13.6; HRMS calcd for C₂₂H₃₆N₂O₁₂Na (M+Na): 543.2166, found 543.2175. Compound **9**: ¹H NMR (500 MHz, D₂O) δ 4.95 (d, *J* = 3.8 Hz, 1H), 4.16 (dd, *J* = 6.2, 3.8 Hz, 1H), 4.02 (dd, *J* = 7.1, 3.8 Hz, 1H), 3.95 (q, *J* = 6.5 Hz, 1H), 3.88 (d, *J* = 7.1 Hz, 1H), 3.67 (dd, *J* = 11.8, 4.1 Hz, 1H), 3.64-3.53 (m, 3H), 3.60 (br., 1H), 3.51 (dd, *J* = 11.8, 2.2 Hz, 1H), 3.36-3.31 (m, 1H), 2.29-2.05 (m, 4H), 2.09 (t, *J* = 7.3 Hz, 2H), 1.76-1.55 (m, 6H), 1.25-1.05 (m, 2H), 1.03 (d, *J* = 6.5 Hz, 3H); ¹³C NMR (125 MHz, D₂O) δ 182.1, 175.5, 172.4, 92.9, 75.1, 74.6, 72.2, 70.7, 69.9, 68.2, 66.9, 64.9, 53.5, 52.9, 36.2, 33.0, 31.6, 30.5, 28.6, 24.4, 23.5, 21.1, 15.6; HRMS calcd for C₂₂H₃₆N₂O₁₁Cs (M+Cs): 637.1373, found 637.1353.
13. Sasaki, A.; Murahashi, N.; Yamada, H.; Morikawa, A. *Biol. Pharm. Bull.* **1994**, *17*, 680.
 14. Berndt, P.; Fields, G. B.; Tirrell, M. *J. Am. Chem. Soc.* **1995**, *117*, 9515.
 15. Compounds **12** and **16** were obtained as reported in ref 6c. Compound **17** was purchased from Toronto Research Chemicals Inc., Canada.
 16. Compound **13**: ¹H NMR (500 MHz, CDCl₃) δ 4.95 (brs, 1H), 4.56-4.44 (m, 3H), 4.26-4.04 (m, 4H), 3.98-3.88 (m, 1H), 3.87-3.79 (m, 1H), 3.71-3.50 (m, 14H), 3.40-3.31 (m, 3H), 3.09-2.97 (m, 2H), 2.27-2.66 (m, 2H), 2.60-2.31 (m, 6H), 2.17-2.04 (m, 2H), 1.71-1.60 (m, 4H), 1.41-1.23 (m, 52H), 1.16 (d, *J* = 5.5 Hz, 6H), 0.80 (t, *J* = 6.5 Hz, 6H); HRMS calcd for C₆₀H₂₂₁N₄O₁₇Cs (M+Cs): 1319.7233, found 1319.7264. Compound **14**: ¹H NMR (500 MHz, CDCl₃) δ 4.80 (d, *J* = 2.6 Hz, 1H), 4.46 (t, *J* = 8.5 Hz, 1H), 4.42-4.40 (m, 4H), 4.05-3.95 (m, 6H), 3.76-3.43 (m, 6H), 2.23 (t, *J* = 7.7 Hz, 2H), 2.30-2.20 (m, 3H), 2.12-2.01 (m, 2H), 1.98-1.91 (m, 4H), 1.85-1.77 (m, 1H), 1.57-1.50 (m, 4H), 1.25-1.13 (br., >50H), 1.11 (d, *J* = 6.3 Hz, 3H), 1.09 (d, *J* = 6.6 Hz, 3H), 0.78 (t, *J* = 6.7 Hz, 6H); ¹³C NMR (125 MHz, D₂O) δ 178.8, 178.4, 173.6, 172.0, 171.6, 170.0, 163.7, 94.4, 72.5, 71.5, 70.5, 69.7, 69.2, 66.9, 66.1, 65.3, 60.2, 59.2, 55.9, 52.1, 49.5, 49.3, 49.3, 49.2, 49.2, 49.1, 49.1, 49.8, 48.8, 48.8, 48.7, 48.7, 48.6, 48.6, 48.5, 42.6, 38.2, 37.0, 34.0, 32.3, 31.7, 31.0, 30.0, 29.9, 29.7, 29.6, 28.9, 28.8, 26.2, 26.6, 23.0, 16.1, 14.6, 14.3; HRMS calcd for C₅₉H₁₀₆N₄O₁₆Cs (M+Cs): 1259.6658, found 1259.6620.
 17. New, R. R. C. In *Liposomes: A Practical Approach*; New, R. R. C., Ed.; Oxford University press: Oxford, **1990**, p 33-104.
 18. Compound **20**: ¹H NMR (500 MHz, CDCl₃) δ 8.37 (br, 1H), 7.94 (br, 1H), 7.51 (br, 1H), 6.63 (br, 1H), 4.94 (br, 1H), 4.65-4.53 (m, 3H), 3.89-3.43 (m, 23H), 2.36 (br, 4H), 2.24 (t, *J* = 7.0 Hz, 4H), 2.18 (t, *J* = 7.5 Hz, 2H), 1.92 (br, 2H), 1.59 (br, 2H), 1.54-1.47 (m, 4H), 1.36-1.11 (m, 26H), 0.88 (t, *J* = 6.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 177.1, 1.74.1, 174.0, 172.5, 169.8, 77.6, 77.4, 70.2, 69.8, 65.3, 65.2, 39.1, 36.5, 31.9, 29.6, 29.5, 29.3, 29.2, 29.1, 29.0, 28.8, 28.8, 28.3, 25.7, 22.7, 19.2, 16.2, 14.7, 14.1; HRMS calcd for C₅₂H₉₀N₄O₁₆Cs (M+Cs⁺): 1159.5406, found 1159.5438.
 19. Storrs, R. W.; Tropper, F. D.; Li, H. Y.; Song, C. K.; Kuniyoshi, J. K.; Sipkins, D. A.; Li, K. C. P.; Bednarski, M. D. *J. Am. Chem. Soc.* **1995**, *117*, 7301.